Uganda: DHAPP—Uganda People’s Defense Force (UPDF) Partnership for Sustainable HIV Epidemic Control

NOTE: Application submissions for this narrative are due by 5pm ET on January 27, 2021. Submission received after the deadline will not be considered for funding.

Introduction

The HIV/AIDS epidemic has been devastating and negatively affected many militaries and other uniformed organizations worldwide by reducing military readiness, limiting deployments, causing physical and emotional decline in infected individuals and their families, posing risks to military personnel and their extended communities, and impeding peacekeeping activities. As HIV management improves, many of these impacts are disappearing, however, militaries now need to sustain life-long HIV treatment for their HIV-infected beneficiaries in addition to other long-term chronic disease management issues.

The U.S. Government (USG) has a long history of international collaboration and partnerships in the fight against HIV/AIDS, providing funding, technical assistance, and program support. These collaborations are all contributing to HIV epidemic control.

Over the years, the United States Department of Defense (DoD) HIV/AIDS Prevention Program (DHAPP) has successfully engaged over 80 countries in an effort to control the HIV epidemic among their respective military services. DHAPP is the DoD implementing agency collaborating with the U.S. Department of State, the Health Resources and Services Administration, Peace Corps, U.S. Agency for International Development (USAID), and the Centers for Disease Control and Prevention (CDC), in the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). DHAPP receives funding for its programs from two sources: a congressional plus-up to the Defense Health Program (DHP) and funding transfers from the Department of State for PEPFAR. Working closely with DoD, U.S. Unified Combatant Commanders, Joint United Nations Programme on HIV/AIDS (UNAIDS), university collaborators, and other nongovernmental organizations (NGOs), DHAPP’s mission is to build capable military partners through military-specific, culturally focused, HIV/AIDS cooperation and assistance.

In the Defense Security Cooperation Agency guidance, the U.S. Secretary of Defense has identified HIV/AIDS in foreign militaries as a national security issue. Pursuing HIV/AIDS activities with foreign militaries is clearly tied to security interests, regional stability, humanitarian concerns, counterterrorism, and peacekeeping efforts due to the impact of HIV/AIDS as a destabilizing factor in developing societies. DHAPP employs an integrated bilateral and regional strategy for HIV/AIDS cooperation and security assistance. DHAPP implements bilateral and regional strategies in coordination with respective Combatant Commands (COCOMs) and Country Support Teams to offer military-to-military HIV/AIDS program assistance using country priorities set by the U.S. Under Secretary of Defense for Policy and by the Office of the Global AIDS Coordinator (OGAC). DHAPP provides strategic information and supports defense forces in HIV prevention, care, and treatment for HIV-infected individuals and their families.
PEPFAR adopted the UNAIDS global 95-95-95 (formerly 90-90-90) goals that state by 2030: 95% of people with HIV are diagnosed, 95% of them are on antiretroviral therapies (ART) and 95% of them are virally suppressed.

PEPFAR Monitoring, Evaluation, and Reporting (MER) indicators are collected and reported to efficiently use data to drive decision-making and focus HIV programming in the right geographic areas. DHAPP uses the same program indicators for DHP and PEPFAR funded programs. DHAPP collects MER indicator results on a quarterly, semi-annual, and annual basis, depending on indicator and data are reported at the site level to DHAPP. These data allow DHAPP to analyze and evaluate gaps in programming and achievement and identify needs for shifts to reach our shared goals. Due to security sensitivities regarding military site locations and troop movement, all site-level data are analyzed at DHAPP headquarters and summary data are reported to OGAC so that other USG country team agencies can review military program results aggregated at the national level.

Transition to Local Partners: Local partners are encouraged to apply to this announcement. To sustain epidemic control, it is critical that the full range of HIV prevention and treatment services are owned and operated by local institutions, governments, and community-based and community-led organizations – regardless of current antiretroviral (ARV) coverage levels. The intent of the transitioning to local partners is to increase the delivery of direct HIV services, along with non-direct services provided at the site, and establish sufficient capacity, capability, and durability of these local partners to ensure successful, long-term, local partner engagement and impact.

All respondents must demonstrate the active support of the in-country military and the DoD representative in the corresponding U.S. Embassy in the planning and execution of their proposals.

In fiscal year (FY) 2019, DHAPP supported 52 active HIV programs, mainly through direct military-to-military cooperation in addition to support from contracting external organizations and academic institutions to assist with specific aspects of proposed programs. Partners in FY19 included 35 Non-Governmental Organizations (NGO)s and universities working in 46 countries.

Budget

PEPFAR activities and services and corresponding budgets and expenditures are uniformly organized into a classification structure referred to as PEPFAR Financial Classifications. In this structure, the PEPFAR funded activities and services are classified systematically as interventions, which is a combination of programs (and sub-programs) and beneficiaries (and sub beneficiaries). Budget and program expenditures are further arrayed according to the cost classification. The below link contains the PEPFAR Financial Classifications Reference Guide and summaries of these classification definitions.

https://datim.zendesk.com/hc/en-us/articles/360015671212-PEPFAR-Financial-Classifications-Reference-Guide. The estimate budget for this program announcement in the format of the PEPFAR Financial Classifications is as follows:
## Estimated Budget to be used as a Framework

<table>
<thead>
<tr>
<th>Program Management</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Phase 4</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>IM Program Management-NSD (Non-targeted population: Not disaggregated)</td>
<td>$877,011</td>
<td>$877,011</td>
<td>$877,011</td>
<td>$877,011</td>
<td>$3,508,044</td>
</tr>
<tr>
<td>IM Program Management-NSD (Key Populations: Not disaggregated)</td>
<td>$28,066</td>
<td>$28,066</td>
<td>$28,066</td>
<td>$28,066</td>
<td>$112,264</td>
</tr>
<tr>
<td>Care &amp; Treatment</td>
<td>$1,539,215</td>
<td>$1,539,215</td>
<td>$1,539,215</td>
<td>$1,539,215</td>
<td>$6,156,860</td>
</tr>
<tr>
<td>HIV Clinical Services-SD (Non-targeted pop: Young people and adolescents)</td>
<td>$297,213</td>
<td>$297,213</td>
<td>$297,213</td>
<td>$297,213</td>
<td>$1,188,852</td>
</tr>
<tr>
<td>HIV Laboratory Services (Military &amp; other uniformed services)</td>
<td>$60,800</td>
<td>$60,800</td>
<td>$60,800</td>
<td>$60,800</td>
<td>$243,200</td>
</tr>
<tr>
<td>HIV Clinical Services-NSD (Adult women)</td>
<td>$31,707</td>
<td>$31,707</td>
<td>$31,707</td>
<td>$31,707</td>
<td>$126,828</td>
</tr>
<tr>
<td>HIV Clinical Services-NSD (Non-Disaggregated)</td>
<td>$986,537</td>
<td>$986,537</td>
<td>$986,537</td>
<td>$986,537</td>
<td>$3,946,148</td>
</tr>
<tr>
<td>Non-Disaggregated - NSD (Non-Disaggregated)</td>
<td>$86,958</td>
<td>$86,958</td>
<td>$86,958</td>
<td>$86,958</td>
<td>$347,832</td>
</tr>
<tr>
<td>Non-Disaggregated-NSD (Military &amp; other uniformed services)</td>
<td>$76,000</td>
<td>$76,000</td>
<td>$76,000</td>
<td>$76,000</td>
<td>$304,000</td>
</tr>
<tr>
<td>Prevention</td>
<td>$984,228</td>
<td>$984,228</td>
<td>$984,228</td>
<td>$984,228</td>
<td>$3,936,912</td>
</tr>
<tr>
<td>VMMC-SD (Military &amp; other uniformed services)</td>
<td>$684,578</td>
<td>$684,578</td>
<td>$684,578</td>
<td>$684,578</td>
<td>$2,738,312</td>
</tr>
<tr>
<td>Category</td>
<td>Cost 1</td>
<td>Cost 2</td>
<td>Cost 3</td>
<td>Cost 4</td>
<td>Cost 5</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Community mobilization, behavior &amp; norms change-SD (Young women &amp; Adolescent females)</td>
<td>$190,000</td>
<td>$190,000</td>
<td>$190,000</td>
<td>$190,000</td>
<td>$760,000</td>
</tr>
<tr>
<td>Primary prevention of HIV and sexual violence-NSD (Pregnant &amp; breastfeeding women)</td>
<td>$75,686</td>
<td>$75,686</td>
<td>$75,686</td>
<td>$75,686</td>
<td>$302,744</td>
</tr>
<tr>
<td>Community mobilization, behavior &amp; norms change-SD (Key pops)</td>
<td>$33,964</td>
<td>$33,964</td>
<td>$33,964</td>
<td>$33,964</td>
<td>$135,856</td>
</tr>
<tr>
<td><strong>Above Site Programming</strong></td>
<td>$91,200</td>
<td>$91,200</td>
<td>$91,200</td>
<td>$91,200</td>
<td>$364,800</td>
</tr>
<tr>
<td>Policy planning, coordination &amp; management of disease control programs-NSD (Military &amp; other uniformed services)</td>
<td>$91,200</td>
<td>$91,200</td>
<td>$91,200</td>
<td>$91,200</td>
<td>$364,800</td>
</tr>
<tr>
<td><strong>HIV Testing Services</strong></td>
<td>$69,805</td>
<td>$69,805</td>
<td>$69,805</td>
<td>$69,805</td>
<td>$279,220</td>
</tr>
<tr>
<td>Community-based testing-SD (Military &amp; other uniformed services)</td>
<td>$14,896</td>
<td>$14,896</td>
<td>$14,896</td>
<td>$14,896</td>
<td>$59,584</td>
</tr>
<tr>
<td>Community-based testing-SD (Key population)</td>
<td>$54,909</td>
<td>$54,909</td>
<td>$54,909</td>
<td>$54,909</td>
<td>$219,636</td>
</tr>
<tr>
<td><strong>Socioeconomic</strong></td>
<td>$131,628</td>
<td>$131,628</td>
<td>$131,628</td>
<td>$131,628</td>
<td>$131,628</td>
</tr>
<tr>
<td>Legal, human rights</td>
<td>$15,200</td>
<td>$15,200</td>
<td>$15,200</td>
<td>$15,200</td>
<td>$60,800</td>
</tr>
</tbody>
</table>
& protection-SD (Orphans & vulnerable children)


Approaches to Reaching Sustainable Epidemic Control

Proposals are requested to support the Uganda People’s Defense Force (UPDF) to reach sustainable control of the HIV/AIDS epidemic through the pillars of transparency, accountability, and impact.

The Recipient’s program should emphasize capacity building across all activities and technical areas. All proposals should detail how the Recipient will engage the partner military leadership as well as personnel at all levels in this work; and, specifically how the partner will utilize the organizational structure of the military to strengthen the internal capacity of the military to conduct these activities. Within the proposal, the Recipient will need to demonstrate transition of programmatic capabilities and capacity to the military over the life of the award.

The Recipient must work in complete coordination with the partner militaries’ HIV prevention and health services, as well as the DHAPP/DoD Program Manager based at the U.S. Embassies in these countries, the DoD adult and pediatric treatment program manager based at the Military Health Department, other DHAPP supported Recipients working in these countries, other bilateral and multilateral agencies with similar objectives and the DHAPP Headquarters Team.

Targets

Progress towards epidemic control will be successfully measured, in part, through an effective strategic information framework that monitors not only program outputs as compared to planned targets, but also key outcomes and programmatic impact.

Collection and use of disaggregated data that characterizes the populations served in the lowest geographic areas where HIV services are being provided is critical in understanding current program performance and planning for future performance. Consequently, the MER indicators continue to evolve in order to reflect the progression of USG support and global HIV response guidelines. Measuring the impact of support at national and regional above-site levels down to direct services at the site-level is paramount to DHAPP’s program implementation and monitoring approach.

MER indicators are not an exhaustive list of all metrics that should be monitored by DHAPP-supported programs. DHAPP also collects a custom indicator. All programs should continually monitor and assess any acute programmatic issues and collect additional data to inform program improvement.

The indicators listed below support a patient-centered program monitoring approach. Per the 2017 WHO Consolidated Guidelines on Person-Centered HIV Patient Monitoring and Case Surveillance, person-centered monitoring refers to a shift from monitoring measuring services (e.g., the number of individuals tested or people on treatment) to monitoring people at the center of their access to
linked HIV and health services. In essence, this marks a shift to better support the clients accessing services by focusing more on their individual health outcomes.

The proposal will address approaches to reaching the following targets for military and civilian populations. Targets are listed using the associated PEPFAR MER Indicator. Please see the most recent MER Indicator Reference Guide for more detail at https://datim.zendesk.com/hc/en-us/articles/360000084446-MER-Indicator-Reference-Guides.

### Prevention

#### Technical Area Targets, Year 1

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Label</th>
<th>Military Only</th>
<th>Civilian</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGYW_PREV</td>
<td>Percentage of adolescent girls and young women (AGYW) that completed at least the DREAMS primary package of evidence-based services/interventions. Number of beneficiaries served by</td>
<td>0</td>
<td>1976 (no denominator available)</td>
</tr>
<tr>
<td>OVC_SERV</td>
<td>PEPFAR OVC programs for children and families affected by HIV</td>
<td>0</td>
<td>5532</td>
</tr>
<tr>
<td>PP_PREV</td>
<td>Number of priority populations (PP) reached with the standardized, evidence-based intervention(s) required that are designed to promote the adoption of HIV prevention behaviors and service uptake Among those who started a course of TPT in the previous reporting period, the number that completed a full course of therapy.</td>
<td>5752</td>
<td>1015</td>
</tr>
<tr>
<td>TB_PREV</td>
<td>Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period.</td>
<td>1266</td>
<td>5066</td>
</tr>
<tr>
<td>VMMC_CIRC</td>
<td></td>
<td>3640</td>
<td>24,360</td>
</tr>
</tbody>
</table>

### Testing

#### Technical Area Targets, Year 1

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Label</th>
<th>Military Only</th>
<th>Civilian</th>
</tr>
</thead>
<tbody>
<tr>
<td>CXCA_SCRN</td>
<td>Percentage of HIV-positive women on ART screened for cervical cancer.</td>
<td>0</td>
<td>44% (3796/8483)</td>
</tr>
<tr>
<td>HTS_INDEX</td>
<td>Number of individuals who were identified and tested using Index testing services and received their results</td>
<td>285</td>
<td>530</td>
</tr>
<tr>
<td>HTS_RECENT</td>
<td></td>
<td>157</td>
<td>135</td>
</tr>
</tbody>
</table>
### Technical Area Targets, Year 1

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Label</th>
<th>Military Only</th>
<th>Civilian</th>
</tr>
</thead>
<tbody>
<tr>
<td>HTS_TST</td>
<td>Number of newly diagnosed HIV-positive persons who received testing for recent infection with a documented result during the reporting period</td>
<td>2154</td>
<td>9183</td>
</tr>
<tr>
<td>PMTCT_EID</td>
<td>Number of individuals who received HIV Testing Services (HTS) and received their test results. Percentage of infants born to HIV-positive women who received a first virologic HIV test (sample collected) by 12 months of age. Percentage of pregnant women with known HIV status at antenatal care (includes those who already knew their HIV status prior to ANC). Percentage of new and relapse TB cases with documented HIV status.</td>
<td>0</td>
<td>100% (2332/2332)</td>
</tr>
<tr>
<td>PMTCT_STAT</td>
<td></td>
<td>0</td>
<td>100% (8847/8847)</td>
</tr>
<tr>
<td>TB_STAT</td>
<td></td>
<td>100% (394/394)</td>
<td>100% (394/394)</td>
</tr>
</tbody>
</table>

### Treatment

#### Technical Area Targets, Year 1

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Label</th>
<th>Military Only</th>
<th>Civilian</th>
</tr>
</thead>
<tbody>
<tr>
<td>PMTCT_ART</td>
<td>Percentage of HIV-positive pregnant women who received ART to reduce the risk of mother-to-child-transmission (MTCT) during pregnancy.</td>
<td>0</td>
<td>98% (2454/2504)</td>
</tr>
<tr>
<td>TB_ART</td>
<td>Number of TB cases with documented HIV-positive status who start or continue ART during the reporting period.</td>
<td>166</td>
<td>159</td>
</tr>
<tr>
<td>TX_CURR</td>
<td>Number of adults and children currently receiving antiretroviral therapy (ART)</td>
<td>8992</td>
<td>15,310</td>
</tr>
<tr>
<td>TX_NEW</td>
<td>Number of adults and children newly enrolled on antiretroviral therapy (ART)</td>
<td>44</td>
<td>441</td>
</tr>
<tr>
<td>TX_TB</td>
<td>Number of ART patients who were screened for TB at least once during the semiannual reporting period.</td>
<td>4858</td>
<td>19431</td>
</tr>
</tbody>
</table>

### Viral Suppression

#### Technical Area Targets, Year 1

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Label</th>
<th>Military Only</th>
<th>Civilian</th>
</tr>
</thead>
</table>
18. TX_PVLS  18. Percentage of ART patients with a suppressed viral load (VL) result (<1000 copies/ml) documented in the medical or laboratory records/laboratory information systems (LIS) within the past 12 months  

<table>
<thead>
<tr>
<th>Military Only</th>
<th>Civilian</th>
</tr>
</thead>
<tbody>
<tr>
<td>95% (10,626/11,185)</td>
<td>95% (10,209/10,747)</td>
</tr>
</tbody>
</table>

Health Systems

Technical Area Targets, Year 1

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Label</th>
<th>Military Only</th>
<th>Civilian</th>
</tr>
</thead>
<tbody>
<tr>
<td>19. EMR_SITE</td>
<td>Number of PEPFAR-supported facilities that have an electronic medical record (EMR) system within the following service delivery areas: HIV Testing Services, Care &amp; Treatment, Antenatal or Maternity Services, Early Infant Diagnosis or Under Five Clinic, or TB/HIV Services</td>
<td>28</td>
<td>0</td>
</tr>
</tbody>
</table>

Technical Narrative

The Recipient will address the technical approach to each area. The Recipient will be responsible for providing the following in close collaboration with other DHAPP-funded Recipients and the host military.

HIV Prevention

The Recipient will ensure that the partner military is providing standardized, evidence-based interventions that are designed to promote the adoption of HIV prevention behaviors and service uptake for all military and other uniformed services as well as other priority populations served by the military health services. These priority populations (PP) should include men that have sex with men (MSM), sex workers and their clients, displaced persons, fishing communities, mobile populations, HIV serodiscordant couples, adolescent girls and young women and illicit drug users.

The Recipient will ensure that the following interventions for adults and youth include:

- Promotion of relevant adult- and youth-friendly prevention and clinical services and demand creation to increase awareness, acceptability, and uptake of these services.
- Information, education, and skills development to reduce HIV risk and vulnerability; correctly identify HIV prevention methods; adopt and sustain positive behavior change; and promote gender equity and supportive norms and stigma reduction.
- Referral to or provision of HIV testing; facilitated linkage to care and prevention services; and/or support services to promote use of, retention in, and adherence to care.
- Condom and lubricant (where feasible) promotion, skills building, and facilitated access to condoms and lubricant (where feasible) through direct provision or linkages to social marketing and/or other service outlets.
• Programs targeting adults to raise awareness of HIV risks for young people, promote positive parenting and mentoring practices, and effective adult-child communication about sexuality and sexual risk reduction.

Voluntary Male Medical Circumcision (VMMC)
The Recipient will ensure that the UPDF is following PEPFAR guidance, WHO recommendations and the national guidelines for conducting VMMC. The full package of VMMC services will be offered, including:
• Demand creation, VMMC education, safe sex practices and provision of condoms
• HIV screening or testing* (see addendum below) for all clients and tracked referral to HIV treatment programs for those who test positive for same-day initiation of ART.
• Examination and evaluation for active sexually transmitted infections (STI).
• STI-positive persons will be deferred from VMMC and referred for immediate treatment of STI, as well as counseled to return and actively invited for VMMC when STI is resolved.
• Post-VMMC wound care (WHO Clean Care) and safe sex education including promotion of 6-week abstinence period post-VMMC.
• Effective monitoring and reporting of VMMC program data and adverse events as well as linked STI and HIV program data.

The Recipient will follow all PEPFAR adverse event reporting protocols for any notifiable adverse events (NAE) occurring during the VMMC procedure or within 30 days following surgical circumcision. This includes notifying the PEPFAR Funding Agency point of contact (POC) and the Uganda PEPFAR Coordinator within 24 hours of the NAE occurring. The Recipient will collaborate with other PEPFAR VMMC Recipients to ensure VMMC coverage in scale up districts and populations.

The Recipient will offer surgical VMMCs to males over 15 years of age ensuring that no boys 15 years or younger, or those with immature penile anatomy are included unless Shang Ring is used (10-14 years of age).

VMMC activities will be implemented concurrently with other component activities such as HIV Testing Services, treatment for STIs, promotion of safer-sex practices and condom distribution.

VMMC Strategy:
9. Recruits: In an effort to offer 100% VMMC coverage in the UPDF in an efficient manner, the Recipient will support the UPDF in their routine offer of VMMC to UPDF recruits within the recruit training period.
10. Active-Duty Males: The Recipient will support the UPDF in holding campaigns at garrisons and camps for VMMC demand creation.
11. Civilians: The Recipient will support the national VMMC program in conducting VMMC for civilians in DoD allocated PEPFAR VMMC scale-up districts, targeting high risk- males between the ages of 15-29 years old.
12. High risk men: The Recipient will build strong referral systems to reach and offer VMMC to: a) STI patients (post-treatment), b) alcohol risk reduction clients, c) partners of HIV positive persons, d) other men who are identified as high risk for HIV.

*Testing in VMMC settings*

Testing in VMMC settings has historically produced very low HIV yields and may be replaced with screening using a validated tool. Validation should be conducted in at least one large VMMC site to determine if the tool is screening out the right people (HIV-negative) yet not also screening out the wrong people (HIV-positive who are not yet diagnosed). Evaluation of the screening tool should include:

- Test a number of men who seek VMMC services based on established sample size calculation using appropriate HIV prevalence estimates.
- The screening tool performance should be compared with universal national HIV testing algorithm results for all persons using a standard two by two table. Screening tool sensitivity, specificity as well as positive and negative predictive values will allow an informed decision to be made on tool performance and guide modifications.
- Test yields for universal and pre-screening should be compared.
- Technical assistance for this work is available from DHAPP.

**Pre-exposure Prophylaxis (PrEP)**

Oral pre-exposure prophylaxis with oral tenofovir or tenofovir-containing regimens has been shown to reduce the risk of HIV acquisition among numerous populations. WHO guidelines recommend offering oral PrEP to those at substantial risk of HIV infection, defined as an incidence rate of or exceeding 3 per 100 persons per year. This level of risk has been seen among sero-discordant couples with inconsistent condom use when the partner living with HIV is not virally suppressed, MSM, transgender women, sex workers (SW) of all genders, people who inject drugs (PWID), and older adolescent girls and young women (AGYW) in many parts of sub-Saharan Africa. DHAPP supports WHO guidelines on the use of PrEP as part of a package of comprehensive prevention services that includes risk reduction education and counselling, condom promotion, VMMC, and structural interventions to reduce vulnerability to HIV infection.

- The Recipient should work with the partner military to identify priority groups, set targets, and plan for PrEP implementation and implementation.
- The Recipient should engage with partner militaries to advance “above-site” PrEP readiness and implementation. These activities may include developing national policies; implementation and operational guidelines; product registration; supporting awareness-building and demand-creation efforts; testing integrated PrEP service delivery models; and exploring private sector engagement. Communication efforts will be needed to educate potential PrEP clients and to train health care providers on PrEP benefits, risks, and procedures. Civil society groups already working with the key and other vulnerable populations should be engaged to assist in outreach.
- High-quality PrEP materials can be found at the following links:
HIV Testing Services

Finding the remaining persons who are living with HIV infection is the first priority for reaching HIV epidemic control. Current epidemiology shows that most of those who do not yet know about their infection are men. The UPDF HIV/AIDS program is strategically placed to reach men; therefore, the Recipient will work closely with the UPDF on HIV Testing Services (HTS), particularly index testing and self-testing, in an effort to achieve the “first 95” for military personnel: 95% of all UPDF personnel living with HIV know their status.

HTS will focus primarily on index testing to provide high-yield testing to those most at risk for infection. The local epidemiology and situational analysis should guide the use of other testing methodologies to identify those who are living with HIV.

Where possible, a rapid test for recent infection (RTRI) should be conducted for all of those found to be newly positive. Those who test positive are classified as “probable recent HIV infections” until results of viral load are available. The index testing of these persons should receive high priority and robust efforts should be made to reach all contacts.

Provider-Initiated Testing and Counseling (PITC) will continue in the fixed sites for both the military and civilian cohorts. PITC should focus in clinical areas that have shown a high yield such as tuberculosis (TB) and STI clinics.

Ensuring that any clients with positive results are linked to HIV care and treatment is essential to the success of the UPDF program. The Recipient should work to achieve 100% linkage of HIV-positive individuals identified. The Recipient will monitor HIV testing yield, modifying strategies or locations that are not identifying and/or linking significant numbers of HIV-positive persons to HIV care and treatment.

The Recipient will be responsible for:

- HTS to military bases and facilities
  - Diagnosing 508 people living with HIV (PLHIV) with 95% of those diagnosed linked to HIV care and treatment services.
  - Index-case testing for all sexual partners of HIV-infected military personnel and civilians.
  - Index-case testing for all children under 15 years of age with HIV-infected mothers.
  - Index clients should also be offered self-testing for partners if they do not volunteer for partner notification.
• HTS to military bases and facilities, ensuring that all of those diagnosed are linked to HIV treatment services and receive same day initiation of ART.
• Self-testing should be made available for military personnel, adolescent girls and young women (AGYW) and their partners, male partners of ANC clients, sex workers, MSM and other key and priority populations (young men and at risk males) that face high levels of stigma and discrimination. Following self-testing, facility referral and the regular diagnostic algorithm can be used according to national standards. It is vital to engage community groups to advocate for, design, implement, and analyze the success of HIVST.
• Quality improvement and quality assurance for all UPDF HTS, including continuous training and mentoring and supervision visits, at least quarterly.
• Conducting proficiency testing for all HTS sites and individuals.
• Tracking PLHIV from HTS to clinical care and treatment services.
• Linking males to VMMC services.

HIV Treatment
Support for treatment of HIV is an essential component of this PA. The following issues should be considered in supporting the treatment of PLHIV in military populations.

Dolutegravir (DTG)-containing regimens are the preferred first-line antiretroviral therapies (ART) due to superior efficacy, tolerability and higher threshold for resistance compared to efavirenz (EFV)-containing regimens. The fixed dose combination (FDC) of tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) is currently priced as the least expensive FDC, and it is expected that prices will go down as generic manufacturing scales up. For these reasons, DHAPP now recommends TLD as the preferred option for ART, and further recommends that DHAPP-supported programs switch over to TLD as soon as possible in a coordinated fashion as supply becomes available.

Programs should carefully assess the risks and benefits of TLD in child-bearing age women. See published updated from WHO and PEPFAR to further understand the high benefits in the face of a potential NTD signal.

Children (< 20kg) are not expected to be included in the initial roll-out of TLD. Development of pediatric DTG formulations and evaluation of appropriate DTG dosing in infants and children are underway.

A priority of HIV programs is to find, diagnose and treat people with TB disease and ensure that they become non-infectious. For all those who do not have active tuberculosis, prevention of TB is a priority using nationally approved TB preventive therapy.

TB preventive therapy (TPT) must be scaled up for all PLHIVs as an integral part of the clinical care package. IPs are expected to increase the use of TB diagnostic testing within DHAPP-supported HIV care and treatment facilities and promote the use of TPT as a routine part of HIV care. In short, all newly diagnosed HIV persons should be offered TB treatment or preventive therapy and all persons assessed for TB should be tested for HIV.

Programs should have clear policies and/or guidelines for the use of TPT, and should plan for
programmatic and clinical trainings, procurement and supply management, adequate diagnostic capacity (including specimen transportation) and development of appropriate data collection systems. In Global Fund high-impact countries implementing joint TB/HIV awards, Recipients should also seek opportunities to support effective joint program implementation.

Additionally, the Recipient should implement TB infection prevention and control activities to minimize the risk of TB transmission and provide safe health seeking environment. This is critical in DHAPP-supported settings where clients at high risk for TB and HIV often co-mingle. It also puts the health care workers at the highest risk of contracting TB disease. Activities aimed at preventing transmission at facility-level include administrative and environmental controls, and the availability and use of personal protective equipment.

Cervical cancer screening for HIV+ women should be integrated into routine HIV treatment services in each country program. A “screen-and-treat” approach is recommended for the management of precancerous lesions to maximize opportunities for immediate cryotherapy or thermal ablation treatment for eligible women without the need for diagnostic pathology confirmation and to reduced loss to follow-up

**Viral Load (VL) Scale-up**

Sustained viral suppression of all PLHIV is the key to HIV epidemic control. To this end, the Recipient will work closely with the UPDF to scale-up VL testing coverage and suppression in an effort to achieve 95-95-95 goals for military personnel. Targets for HIV/AIDS care and treatment will focus on generating significant progress towards the third 95: 95% viral suppression among PLHIV taking ART.

The Recipient should ensure the partner military has access to timely VL testing and that capacity exists to test at least 95% of persons currently on ART annually. To ensure this capacity the appropriate use of both plasma and dried blood spots (DBS) should be considered to increase access to routine viral load monitoring.

DBS are easy to collect and store under field conditions, no phlebotomist required, easy to transport to centralized laboratories, reduced cost associated with collection materials and transportation under ambient temperature. The DBS technology is applicable to both adult and pediatric populations and the small volume of blood required for preparing DBS makes it suitable for pediatric populations.

The Recipient will ensure that VL results are made available in a reasonable amount of time to both the health care provider and the client. These results should be used to ensure that those who are not virally suppressed are linked to adherence support and close follow-up leading to either suppression or ART modification as needed. Those who are suppressed should be encouraged to stay suppressed and should be offered differentiated models of care, including multi-month supplies of ART and fast-tracking as an incentive, and given the message that undetectable equals untransmittable (U=U).

**Health System Strengthening**
DHAPP is working to enhance the ability of governments to manage their epidemics, respond to broader health needs impacting affected communities, and address new and emerging health concerns. Activities include the following:

Laboratory capacity building

The Recipient will be responsible for:

- Inventory control, forecasting, and ensuring the procurement of laboratory reagents to ensure that laboratory services are uninterrupted.
- Procurement of service maintenance contracts, calibration of equipment, and training of the laboratory staff on the use of the equipment.
- Ensuring quality improvement of laboratories using Site Improvement Monitoring System (SIMS), Strengthening Laboratory Management Toward Accreditation (SLMTA) and Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) to reach full ISO 15189 accreditation of main laboratories and quality improvement of all satellite laboratories and HIV test sites.
- Monitoring laboratory quality and adherence to quality systems, method validation, provision of proficiency testing panels for rapid HIV testing, VL, CD4, TB, STI and other tests critical to HIV epidemic control.
- Conducting routine visits to laboratories to assess achievements, review/evaluate activities, and provide recommendations with the development of improvement plans to resolve any identified problems.
- Linking UPDF laboratory services to other laboratory resources at the district, provincial, and national levels.

The procurement of supplies, support, and equipment should use government and other donor sources when possible (Ministry of Health, Ministry of Defense, Global Fund, etc).

DHAPP will continue to reduce its overall level of support for CD4 testing to prioritize access to viral load testing. CD4 count is not needed to determine eligibility for ART (and continued CD4 testing may perpetuate the belief that CD4 count thresholds are criteria for initiating ART) and, as reflected in current WHO guidelines, CD4 is inferior to VL for treatment monitoring.

DHAPP’s priority is access to critical HIV treatment monitoring, which is via VL testing. VL should be conducted at least once annually for stable patients and more frequently for new, unstable and pediatric patients.

Site Improvement through Monitoring System (SIMS)

The purpose of SIMS is to provide a standardized approach and set of tools for monitoring program quality at DHAPP-supported sites and entities that guide and support service delivery. SIMS assessment results are used to strengthen alignment with global and national standards and facilitate program improvement as a component of an overall quality management strategy. SIMS is also used to identify performance issues that may impact patient outcomes or the integrity of reporting for MER targets or disaggregates. Low final scores (reds and yellows) from these core
essential elements (CEEs) highlight potential issues with service delivery, site performance or oversight, and/or documentation of patient results. Site-level triangulation of MER and SIMS data can be used to contextualize performance and could be useful to determine if performance challenges at a site are due to issues related to the underlying quality of service provision.

Site Improvement through Monitoring System (SIMS) aims to: (1) facilitate improvement in the quality of DHAPP-supported services and technical assistance, (2) ensure accountability of U.S. government investments, and (3) maximize impact on the HIV epidemic.

SIMS assessment results confirm compliance to minimum quality assurance standards and identify areas where improvements in DHAPP-supported programs can be made.

Programs should conduct SIMS assessments in accordance with DHAPP guidance and Recipients are responsible for taking corrective action for items within the Recipient SOW and per discussion with DHAPP USG staff.

Client, Patient, and Program Data Monitoring

Successful collection, evaluation, and use of client/patient level data is critical to good patient care and to the success of the partner military HIV program’s ability to monitor progress towards epidemic control. The Recipient will work with the partner military and Ministry of Health (MOH) or other organizations, as appropriate, to support the collection of patient-level data, the clinical and programmatic use of data, and the reporting of site-level data to DHAPP HQ and the partner military leadership.

The Recipient will be responsible for:

- Staffing, support, and mentoring of existing partner military staff for paper and electronic data entry
- Timely, accurate reporting of all indicators required by the partner military and DHAPP
- Ensuring confidentiality and security of data, in line with Ministry of Defense (MOD), MOH, and national guidelines from clinic to storage to dissemination.
- Securing all patient-level and site-level data from dissemination outside of the partner military and DHAPP without prior approval from the partner military
- Supporting paper and electronic data entry, cleaning, reporting, and use

Data Quality

Measuring the success of HIV/AIDS initiatives requires strong monitoring and evaluation (M&E) systems that produce high quality data. Efforts to ensure data quality, therefore, are not singular events occurring randomly. Rather, these processes need to become institutionalized as part of routine data management processes. Once achieved, data quality helps to ensure that limited resources are used effectively, progress toward established goals are accurately monitored, and that decisions are based on strong evidence. Attention to data quality ensures that target-setting and results reporting are informed by valid and sensitive information, and that all partners are thinking about and collecting and organizing this information in the same manner. In this way, attention to data quality leads to improved program performance and to more efficient resource management.
Data quality has always been a focus of global HIV monitoring and reporting efforts. Specifically, all countries conducting programming supported by DHAPP are expected to have a data quality strategy in place. For example, data quality assessments (DQAs) should be conducted routinely and action should be taken as a result of these DQAs. If errors are identified in data, these should be remediated at the point of service delivery as well as in the DHAPP and host-country reporting systems as soon as possible. Standard operating procedures for routine data quality review should also be in place. Data should be routinely reviewed for errors before submission to ensure that the data passes the data quality checks outlined within the guidance, the DC2 validations, and the Data for Accountability, Transparency, and Impact Monitoring (DATIM) Data Review Tool.

**Virtual Communities of Practice**

The Recipient should support the development of virtual communities of practice (vCoP). These evidence-based, virtual, face-to-face health workforce development and collaborative problem-solving platforms, serve to create ongoing dialogue and collaboration among key staff in the military health care systems. They provide a consistent platform for conducting low-dose, high-frequency learning and collaboration sessions. The goal is to build a vCoP for each partner military where DHAPP works in collaboration with DHAPP HQ, field staff and other Recipients working in that country.

Key requirements are equipment and connectivity as well as personnel who can coordinate, manage and lead regular vCoP sessions. These roles may need to be held by the Recipient until they can be transitioned to the partner military.

**Work Plans**

The Recipient must submit annual, programmatic and financial, work plans to the DHAPP Program Manager and DHAPP HQ (budget breakdown per activity and for program management is required). Work plans should include an activities implementation timeline as well as monitoring and evaluation timeline.